Pharmacokinetics of ceftiofur in healthy and lipopolysaccharide-induced endotoxemic newborn calves treated with single and combined therapy

Basit Öğe Kaydı
dc.contributor.authorAltan, Feray
dc.contributor.authorUney, Kamil
dc.contributor.authorEr, Ayse
dc.contributor.authorCetin, Gul
dc.contributor.authorDik, Burak
dc.contributor.authorYazar, Enver
dc.contributor.authorElmas, Muammer
dc.date.accessioned2020-03-26T19:42:18Z
dc.date.available2020-03-26T19:42:18Z
dc.date.issued2017
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractThe aim of this research was to compare plasma pharmacokinetics of ceftiofur sodium (CS) in healthy calves, and in calves with experimentally induced endotoxemia. Six calves received CS (2.2 mg/kg, IM) 2 hr after intravenous administration of 0.9% NaCl (Ceft group). After a washout period, the same 6 calves received CS 2 hr after intravenous injection of lipopolysaccharide (LPS+Ceft group). Another group of 6 calves received a combination of drug therapies that included CS 2 hr after administration of 0.9% NaCl (Comb group). A third group of 6 calves received the same combination therapy regimen 2 hr after intravenous injection of lipopolysaccharide (LPS+Comb group). Plasma concentrations of CS and all desfuroylceftiofurrelated metabolites were determined using HPLC, and its pharmacokinetic properties were determined based on a two-compartment model. The peak concentration of CS in the LPS+Comb group occurred the earliest, and the clearance rate of CS was the highest in the Comb and LPS+ Comb groups (P < 0.05). The elimination half-life of CS in the LPS+Ceft group was longer than that in the Ceft and Comb groups (P < 0.05). The results of this study indicate that combined therapies and endotoxemic status may alter the plasma pharmacokinetics of CS in calves.en_US
dc.description.sponsorshipTUBITAKTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [110O404]en_US
dc.description.sponsorshipThis manuscript summarizes the PhD thesis of Feray Altan. Research was supported by TUBITAK (110O404). The abstract was submitted to the 12th International Congress of the European Association for Veterinary Pharmacology and Toxicology (EAVPT), Amsterdam, Holland, July 2012.en_US
dc.identifier.doi10.1292/jvms.16-0641en_US
dc.identifier.endpage1252en_US
dc.identifier.issn0916-7250en_US
dc.identifier.issn1347-7439en_US
dc.identifier.issue7en_US
dc.identifier.pmid28579597en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1245en_US
dc.identifier.urihttps://dx.doi.org/10.1292/jvms.16-0641
dc.identifier.urihttps://hdl.handle.net/20.500.12395/35373
dc.identifier.volume79en_US
dc.identifier.wosWOS:000411102600018en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherJAPAN SOC VET SCIen_US
dc.relation.ispartofJOURNAL OF VETERINARY MEDICAL SCIENCEen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectcalveen_US
dc.subjectceftiofuren_US
dc.subjectendotoxemiaen_US
dc.subjectpharmacokineticen_US
dc.titlePharmacokinetics of ceftiofur in healthy and lipopolysaccharide-induced endotoxemic newborn calves treated with single and combined therapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu